Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 1, 2003, Pages 9-15

  Rolleman, Edgar J ^a   Valkema, Roelf ^a   De Jong, Marion ^a   Kooij, Peter P M ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hyperkalaemia; Kidney; Lysine; Octreotide; PRRT

Indexed keywords

ARGININE; LYSINE; PENTETREOTIDE IN 111;

AMINO ACID COMPOSITION; ARTICLE; CANCER LOCALIZATION; CANCER SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERKALEMIA; KIDNEY TUBULE ABSORPTION; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; VOMITING;

ARGININE; CARCINOMA, NEUROENDOCRINE; FEMALE; HUMANS; HYPERKALEMIA; INFUSIONS, INTRAVENOUS; KIDNEY; LYSINE; NEUROENDOCRINE TUMORS; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICALS; VOMITING;

EID: 0037601663     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0982-3     Document Type: Article

References (32)

1. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731.
2. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26-34.
3. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704-1713.
4. 111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci 1994; 733:496-506.
5. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32:110-122.
6. Otte A, Herrmann R, Heppeler A, et al, Yttrium-90 DOTA-TOC: first clinical results. Eur J Nucl Med 1999; 26:1439-1447.
7. 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426-434.
8. 0] octreotide in patients. Eur J Nucl Med 2001; 28:1319-1325.
9. 3-octreotate in patients with somatostatin receptor positive tumors:preliminary results. J Nucl Med 2001; 42(5 Suppl):37P.
10. Valkema R, De Jong M, Kooij PPM, et al. Effective and safe inhibition of renal uptake of radiolabeled peptides by combined lysine and arginine infusion. J Nucl Med 2001; 42(5 Suppl):37P.
11. 3]octreotide (DOTATOC). J Nucl Med 2001; 42(5 Suppl):37P.
12. 90Y-DOTATOC. Eur J Nucl Med 2001; 28: 1552-1554.
13. Stoffel MP, Pollok M, Fries J, et al. Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma. Nephrol Dial Transpl 2001; 16:1082-1083.
14. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001; 37:847-851.
15. de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996; 37:1388-1392.
16. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25:201-212.
17. Duncan JR, Stephenson MT, Wu HP, et al. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997; 57:659-671.
18. Mogensen CE, Solling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977; 37:477-486.
19. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993; 67:1437-1439.
20. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995; 55:3825-3834.
21. Barone R, Jamar F, Walrand S, et al. Amino acids infusion for renal protection during radiolabeled peptide therapy: comparison between different infusion regimens. Eur J Nucl Med 2000; 27:976.
22. 90Y-DOTATOC therapy. J Nucl Med 2000; 41:267P.
23. Sartori S, Nielsen I, Pennacchio G, et al. Hyperkalaemia during infusion of hyperosmolar amino acid solutions enriched with branched chain amino acids. Report of two cases. Recent Prog Med 1991; 82:275-277.
24. Massara F, Martelli S, Ghigo E, et al. Arginine-induced hypophosphatemia and hyperkaliemia in man. Diabetes Metab 1979; 5:297-300.
25. Massara F, Cagliero E, Bisbocci D, et al. The risk of pronounced hyperkalaemia after arginine infusion in the diabetic subject. Diabetes Metab 1981; 7:149-153.
26. Barone R, De Camps J, Smith C, et al. Metabolic effect of amino acids (AA) solutions infused for renal radioprotection. J Nucl Med 2000; 41:94P.
27. Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med 1978; 89:632-634.
28. Perazella MA, Biswas P. Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis 1999; 33:782-785.
29. Kaandorp YAM, Jacobs JJA, Valkema R, et al. Renal uptake and renal function, before and after In-111-DTPA-octreotide therapy. Eur J Nucl Med 2000; 27:1224.
30. 111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991; 49:1593-1601.
31. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21:109-122.
32. Moulder JE, Fish BL, Cohen EP. Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. Int J Radiat Biol 1998; 73:415-421.